Skip to content
TrialMatch
Sign up
Recruiting Phase 3

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Create a profile to match View the full record on ClinicalTrials.gov

About this study

This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.

Condition
Metastatic Melanoma, Unresectable Melanoma, Melanoma
Tested
Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period
Sponsor
Iovance Biotherapeutics, Inc.

Who can join

Age
18 to 70 years
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 10

  • Minimum age: 18 years
  • Maximum age: 70 years
  • Study condition: Metastatic Melanoma, Unresectable Melanoma, Melanoma
  • Participant has a histologically or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma.
  • In the investigator's assessment, the participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of \> 6 months.
  • Participant is assessed as having at least one resectable lesion (or aggregate lesions) for lifileucel generation.
  • Participant must have at least one measurable disease as defined by RECIST 1.1 following tumor resection.
  • Participants must have adequate organ function.
  • Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control.
  • Participants who are \> 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.

Exclusion 10

  • Participant has melanoma of uveal/ocular origin.
  • Participant has symptomatic untreated brain metastases.
  • Participant received more than 1 prior line of therapy.
  • Participant received prior therapy for metastatic disease
  • Participants with a BRAF V600 mutation-positive tumor received prior adjuvant/neoadjuvant ICI therapy only
  • Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation, such as systemic infections; seizure disorders; coagulation disorders; or other active major medical illnesses of the cardiovascular, respiratory, or immune systems.
  • Participant has any form of primary or acquired immunodeficiency (eg, SCID or AIDS).
  • Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or were curatively treated \>1 year ago, and in the judgment of the investigator do not pose a significant risk of recurrence.)
  • Participant has a history of allogeneic cell or organ transplant.
  • Other protocol defined inclusion/exclusion criteria could apply.

Where

82 sites, 71 recruiting

Flinders Medical Centre

Bedford Park, Australia

Recruiting

Greenslopes Private Hospital

Greenslopes, Queensland, Australia

Recruiting

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia

Recruiting

Fiona Stanley Hospital

Murdoch, Western Australia, Australia

Recruiting

Westmead Hospital

Westmead, Australia

Recruiting

Universitair Ziekenhuis Brussel - Oncologisch Centrum

Jette, Belgium

Recruiting

and 76 more sites on ClinicalTrials.gov

Contact

Potential match only. Final eligibility is determined by the study team.